Psyence BioMed Initiates Phase IIb Patient Dosing for Psilocybin Candidate NPX-5
PBM has more than doubled off its 52-week low of $1.92.
Summary
Psyence BioMed has initiated patient dosing in its Phase IIb clinical trial for NPX-5, a nature-derived psilocybin candidate, targeting Adjustment Disorder in cancer patients.
Key Events · Product Development and Regulatory · PBM
-
Phase IIb Dosing Initiated
The company announced the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for Adjustment Disorder in cancer patients.
-
Advancing Core Pipeline
This milestone represents the first active clinical evaluation of NPX-5 and signifies the company's transition into systematic human data generation across its Australian clinical network.
-
Addressing Unmet Need
The trial targets psychological distress associated with life-limiting illness, aiming to provide new treatment options in palliative care.
Analysis · PBM · Life Sciences
This marks a critical advancement for Psyence BioMed as it transitions into systematic human data generation for NPX-5, its GMP-compliant, nature-derived psilocybin candidate. Initiating a Phase IIb trial is a significant de-risking milestone for a clinical-stage biopharmaceutical company, demonstrating progress in its core development pipeline. The study aims to evaluate the safety and efficacy of NPX-5 for Adjustment Disorder in cancer patients within a palliative care setting, addressing a significant unmet medical need.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.4% of the 1170 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBM was trading at $9.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $1.92 to $74.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.